Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of DARZALEX® (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma

New formulation also showed shorter administration time and lower rate of infusion-related reactions CHICAGO, June 2, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 COLUMBA (MMY3012) study, investigating a...

from PR Newswire: http://bit.ly/2WEdF5g